Document:

Exhibit
        10.12

      SECURITIES
        PURCHASE AGREEMENT

       

      This
        Securities Purchase Agreement (this “Agreement”)
        is
        dated as of January ______, 2007, by and among BIO-BRIDGE SCIENCE, INC.,
        a
        Delaware corporation (the “Company”),
        and
        the purchasers listed in the exhibit and identified on the signature pages
        hereto (each, including its successors and assigns, a “Purchaser”
and
        collectively the “Purchasers”).

       

      WHEREAS,
        subject to the terms and conditions set forth in this Agreement and pursuant
        to
        Section 4(2) of the Securities Act of 1933, as amended (the “Securities
        Act”)
        and
        Regulation S promulgated thereunder, the Company desires to issue and sell
        to
        each Purchaser, and each Purchaser, severally and not jointly, desires to
        purchase from the Company, securities of the Company as more fully described
        in
        this Agreement.

       

      NOW,
        THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
        and for other good and valuable consideration the receipt and adequacy of
        which
        are hereby acknowledged, the Company and each Purchaser agrees as
        follows:

       

       

      ARTICLE
        I

      DEFINITIONS

       

      1.1          
        Definitions. 
        In addition to the terms defined elsewhere in this Agreement: (a) capitalized
        terms that are not otherwise defined herein have the meanings given to such
        terms in the Certificate of Designation (as defined herein), and (b) the
        following terms have the meanings indicated in this Section 1.1:

       

      “Action”
shall
        have the meaning ascribed to such term in Section 3.1(j).

       

       “Actual
        Minimum”
means,
        as of any date, the maximum aggregate number of shares of Common Stock then
        issued or potentially issuable in the future pursuant to the Transaction
        Documents, including any Underlying Shares issuable upon exercise or conversion
        in full of all Warrants and shares of Preferred Stock, ignoring any conversion
        or exercise limits set forth therein, and assuming that any previously
        unconverted shares of Preferred Stock are held until the second anniversary
        of
        the date of determination and all dividends are paid in shares of Common
        Stock
        until such second anniversary.

       

      “Affiliate”
means
        any Person that, directly or indirectly through one or more intermediaries,
        controls or is controlled by or is under common control with a Person, as
        such
        terms are used in and construed under Rule 144 under the Securities Act. 
With respect to a Purchaser, any investment fund or managed account that
        is
        managed on a discretionary basis by the same investment manager as such
        Purchaser will be deemed to be an Affiliate of such Purchaser.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      “Certificate
        of Designation”
means
        the Certificate of Designation Designating Series A Convertible Preferred
        Stock
        to be filed by the Company with the Secretary of State of Delaware.

       

      “Closing”
means
        the closing of the purchase and sale of the Securities pursuant to Section
        2.1.

       

       “Closing
        Date”
means
        the Trading Day when all of the Transaction Documents have been executed
        and
        delivered by the applicable parties thereto, and all conditions precedent
        to (i)
        the Purchasers’ obligations to pay the Subscription Amount and (ii) the
        Company’s obligations to deliver the Securities have been satisfied or
        waived.

       

      “Commission”
means
        the Securities and Exchange Commission.

       

      “Common
        Stock”
means
        the common stock of the Company, par value $0.001 per share, and any securities
        into which such common stock shall hereinafter have been reclassified
        into.

       

      “Common
        Stock Equivalents”
means
        any securities of the Company or the Subsidiaries which would entitle the
        holder
        thereof to acquire at any time Common Stock, including without limitation,
        any
        debt, preferred stock, rights, options, warrants or other instrument that
        is at
        any time convertible into or exchangeable for, or otherwise entitles the
        holder
        thereof to receive, Common Stock.

       

      “Company
        Counsel”
means
        Richardson & Patel LLP.

       

       “Conversion
        Price”
shall
        have the meaning ascribed to such term in the Certificate of
        Designation.

       

      “Disclosure
        Schedules”
shall
        have the meaning ascribed to such term in Section 3.1 hereof.

       

      “Effective
        Date”
means
        the date that the initial Registration Statement filed by the Company pursuant
        to the Registration Rights Agreement is first declared effective by the
        Commission.

       

      “Exchange
        Act”
means
        the Securities Exchange Act of 1934, as amended.

       

      “Exempt
        Issuance”
means
        the issuance of (a) shares of Common Stock or options to consultants, employees,
        proposed employees, officers or directors of the Company pursuant to any
        stock
        plan or option plan or agreements duly adopted by the Board of Directors
        of the
        Company , (b) securities upon the exercise of or conversion of any securities
        issued hereunder, convertible securities, options or warrants issued and
        outstanding on the date of this Agreement, and (c) securities issued pursuant
        to
        acquisitions or strategic transactions, provided any such issuance shall
        only be
        to a Person which is, itself or through its subsidiaries, an operating company
        in a business synergistic with the business of the Company and in which the
        Company receives benefits in addition to the investment of funds, but shall
        not
        include a transaction in which the Company is issuing securities primarily
        for
        the purpose of raising capital or to an entity whose primary business is
        investing in securities, and (d) securities issued to Corporation service
        provider in lieu of cash compensation.

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

       “GAAP”
shall
        have the meaning ascribed to such term in Section 3.1(g).

       

      “Liens”
means
        a
        lien, charge, security interest, encumbrance, right of first refusal, preemptive
        right or other restriction.

       

       “Material
        Adverse Effect”
shall
        have the meaning assigned to such term in Section 3.1(a).

       

      “Material
        Permits”
shall
        have the meaning ascribed to such term in Section 3.1(l).

       

      “Person”
means
        an individual or corporation, partnership, trust, incorporated or unincorporated
        association, joint venture, limited liability company, joint stock company,
        government (or an agency or subdivision thereof) or other entity of any
        kind.

       

      “Preferred
        Stock”
means
        the up to 4,000,000 shares of the Company’s Series A Convertible Preferred Stock
        issued hereunder having the rights, preferences and privileges set forth
        in the
        Certificate of Designation.

       

      “Proceeding”
means
        an action, claim, suit, investigation or proceeding (including, without
        limitation, an investigation or partial proceeding, such as a deposition),
        whether commenced or threatened.

       

      “Registration
        Rights Agreement”
means
        the Registration Rights Agreement, dated the date hereof, among the Company
        and
        the Purchasers.

       

      “Registration
        Statement”
means
        a
        registration statement meeting the requirements set forth in the Registration
        Rights Agreement and covering the resale of the Underlying Shares by each
        Purchaser as provided for in the Registration Rights Agreement.

       

       “Required
        Approvals”
shall
        have the meaning ascribed to such term in Section 3.1(d).

       

      “Rule
        144”
means
        Rule 144 promulgated by the Commission pursuant to the Securities Act, as
        such
        Rule may be amended from time to time, or any similar rule or regulation
        hereafter adopted by the Commission having substantially the same effect
        as such
        Rule.

       

      “SEC
        Reports”
shall
        have the meaning ascribed to such term in Section 3.1(g).

       

      “Securities”
means
        the Preferred Stock, the Warrants and the Underlying Shares.

       

      “Securities
        Act”
means
        the Securities Act of 1933, as amended.

       

      “Stated
        Value”
means
        $0.75 per share of Series A Convertible Preferred Stock.

       

      “Subscription
        Amount”
shall
        mean, as to each Purchaser, the amount to be paid for the Preferred Stock
        purchased hereunder as specified below such Purchaser’s name on the signature
        page of this Agreement and next to the heading “Subscription Amount”, in United
        States Dollars and in immediately available funds.

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

       

      “Subsidiary”
means
        any subsidiary of the Company .

       

      “Trading
        Day”
means
        a
        day on which the Common Stock is traded on a Trading Market.

       

      “Trading
        Market”
means
        the following markets or exchanges on which the Common Stock is listed or
        quoted
        for trading on the date in question: the Over-The-Counter Bulletin Board,
        the
        Nasdaq Capital Market, the American Stock Exchange, the New York Stock Exchange,
        the Nasdaq Global Market or the Nasdaq Global Select Market.

       

       “Transaction
        Documents”
means
        this Agreement, the Certificate of Designation, the Warrants, the Registration
        Rights Agreement and any other documents or agreements executed in connection
        with the transactions contemplated hereunder.

       

      “Underlying
        Shares”
means
        the shares of Common Stock issuable upon conversion of the Preferred Stock,
        upon
        exercise of the Warrants and issued and issuable in lieu of the cash payment
        of
        dividends on the Preferred Stock.

       

      “Warrants”
means
        collectively the Common Stock purchase warrants delivered to the Purchasers
        at
        the Closing in accordance with Section 2.2(a) hereof, which Warrants shall
        be
        exercisable immediately and have a term of exercise equal to 3
        years.

       

      “Warrant
        Shares”
means
        the shares of Common Stock issuable upon exercise of the Warrants.

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

      

      ARTICLE
        II

      PURCHASE
        AND SALE

       

      2.1         Closing. 
        On the Closing Date, upon the terms and subject to the conditions set forth
        herein, concurrent with the execution and delivery of this Agreement by the
        parties hereto, the Company agrees to sell, and each Purchaser agrees to
        purchase in the aggregate, severally and not jointly $3,000,000 of shares
        of
        Preferred Stock with an aggregated Stated Value equal to such Purchaser’s
        Subscription Amount and Warrants as determined by pursuant to Section
        2.2(a)(iii).  The aggregate number of shares of Preferred Stock sold
        hereunder shall be 4,000,000.  Each Purchaser shall deliver to the Company
        via wire transfer or a certified check immediately available funds equal
        to
        their Subscription Amount and the Company shall deliver to each Purchaser
        their
        respective shares of Preferred Stock and Warrants as determined pursuant
        to
        Section 2.2(a) and the other items set forth in Section 2.2 issuable at the
        Closing.  Upon satisfaction of the conditions set forth in Section 2.2, the
        Closing shall occur at the offices of Bio-Bridge Science, Inc., or such other
        location as the parties shall mutually agree to.

       

      2.2         Deliveries.

       

      
        	
              	a)	
                On
                  the Closing Date, the Company shall deliver or cause to be delivered
                  to
                  each Purchaser the following:

              

      

       

      
        	
              	(i)	
                this
                  Agreement duly executed by the
                  Company;

              

      

       

      
        	
              	(ii)	
                a
                  certificate or document evidencing a number of shares of Preferred
                  Stock
                  equal to such Purchaser’s Subscription Amount divided by the Stated Value,
                  registered in the name of such
                  Purchaser;

              

      

       

      
        	
              	(iii)	
                a
                  Warrant registered in the name of such Purchaser to purchase up
                  to a
                  number of shares of Common Stock equal to 100% of such Purchaser’s
                  Subscription Amount divided by the Exercise Price of Warrants immediately
                  prior to the Closing Date, with the Exercise Price equal to
                  $1.00;

              

      

       

      
        	
              	(iv)	
                the
                  Registration Rights Agreement duly executed by the Company;
                  and

              

      

       

      
        	
              	b)	
                On
                  the Closing Date, each Purchaser shall deliver or cause to be delivered
                  to
                  the Company the following:

              

      

       

      
        	
              	(i)	
                this
                  Agreement duly executed by such
                  Purchaser;

              

      

       

      
        	
              	(ii)	
                such
                  Purchaser’s Subscription Amount by wire transfer to the account as
                  specified in writing by the Company or by writing a check to the
                  Company;
                  and

              

      

       

      
        	
              	(iii)	
                the
                  Registration Rights Agreement duly executed by such
                  Purchaser.

              

      

       

      2.3         Closing
        Conditions.

       

      
        	
              	a)	
                The
                  obligations of the Company hereunder in connection with the Closing
                  are
                  subject to the following conditions being
                  met:

              

      

       

      
        	
              	(i)	
                the
                  accuracy in all material respects when made and on the Closing
                  Date of the
                  representations and warranties of the Purchasers contained
                  herein;

              

      

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      
        	
              	(ii)	
                all
                  obligations, covenants and agreements of the Purchasers required
                  to be
                  performed at or prior to the Closing Date shall have been performed;
                  and

              

      

       

      
        	
              	(iii)	
                the
                  delivery by the Purchasers of the items set forth in Section 2.2(b)
                  of
                  this Agreement.

              

      

       

      
        	
              	b)	
                The
                  respective obligations of the Purchasers hereunder in connection
                  with the
                  Closing are subject to the following conditions being
                  met:

              

      

       

      
        	
              	(i)	
                the
                  accuracy in all material respects when made and on the Closing
                  Date of the
                  representations and warranties of the Company contained
                  herein;

              

      

       

      
        	
              	(ii)	
                all
                  obligations, covenants and agreements of the Company required to
                  be
                  performed at the Closing Date shall have been
                  performed;

              

      

       

      
        	
              	(iii)	
                the
                  delivery by the Company of the items set forth in Section 2.2(a)
                  of this
                  Agreement;

              

      

       

      
        	
              	(iv)	
                there
                  shall have been no Material Adverse Effect with respect to the
                  Company
                  since the date hereof; and

              

      

       

      
        	
              	(v)	
                from
                  the date hereof to the Closing Date, trading in the Common Stock
                  shall not
                  have been suspended by the Commission (except for any suspension
                  of
                  trading of limited duration agreed to by the Company, which suspension
                  shall be terminated prior to the Closing), and, at any time prior
                  to the
                  Closing Date, trading in securities generally as reported by Bloomberg
                  Financial Markets shall not have been suspended or limited, or
                  minimum
                  prices shall not have been established on securities whose trades
                  are
                  reported by such service, or on any Trading Market, nor shall a
                  banking
                  moratorium have been declared either by the United States or Illinois
                  State authorities nor shall there have occurred any material outbreak
                  or
                  escalation of hostilities or other national or international calamity
                  of
                  such magnitude in its effect on, or any material adverse change
                  in, any
                  financial market which, in each case, in the reasonable judgment
                  of each
                  Purchaser, makes it impracticable or inadvisable to purchase the
                  Preferred
                  Stock at the Closing.

              

      

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

       

      ARTICLE
        III

      REPRESENTATIONS
        AND WARRANTIES

       

      3.1         Representations
        and Warranties of the Company. 
        Except as set forth under the corresponding section of the disclosure schedules
        delivered to the Purchasers concurrently herewith (the “Disclosure
        Schedules”)
        which
        Disclosure Schedules shall be deemed a part hereof, the Company hereby makes
        the
        representations and warranties set forth below to each Purchaser.

       

      (a)         
        Organization
        and Qualification. 
        Each of the Company and the Subsidiaries is an entity duly incorporated or
        otherwise organized, validly existing and in good standing under the laws
        of the
        jurisdiction of its incorporation or organization (as applicable), with the
        requisite power and authority to own and use its properties and assets and
        to
        carry on its business as currently conducted.  Neither the Company nor any
        Subsidiary is in violation or default of any of the provisions of its respective
        certificate or articles of incorporation, bylaws or other organizational
        or
        charter documents.  Each of the Company and the Subsidiaries is duly
        qualified to conduct business and is in good standing as a corporation
        or other entity in each jurisdiction in which the nature of the business
        conducted or property owned by it makes such qualification necessary, except
        where the failure to be so qualified or in good standing, as the case may
        be,
        could not have or reasonably be expected to result in (i) a material adverse
        effect on the legality, validity or enforceability of any Transaction Document,
        (ii) a material adverse effect on the results of operations, assets, business,
        prospects or financial condition of the Company and the Subsidiaries, taken
        as a
        whole, or (iii) a material adverse effect on the Company’s ability to perform in
        any material respect on a timely basis its obligations under any Transaction
        Document (any of (i), (ii) or (iii), a “Material
        Adverse Effect”)
        and no
        Proceeding has been instituted in any such jurisdiction revoking, limiting
        or
        curtailing or seeking to revoke, limit or curtail such power and authority
        or
        qualification.

       

      (b)         
        Authorization;
        Enforcement. 
        The Company has the requisite corporate power and authority to enter into
        and to
        consummate the transactions contemplated by each of the Transaction Documents
        and otherwise to carry out its obligations thereunder.  The execution and
        delivery of each of the Transaction Documents by the Company and the
        consummation by it of the transactions contemplated thereby have been duly
        authorized by all necessary action on the part of the Company and no further
        action is required by the Company in connection therewith other than in
        connection with the Required Approvals.  Each Transaction Document has been
        (or upon delivery will have been) duly executed by the Company and, when
        delivered in accordance with the terms hereof, will constitute the valid
        and
        binding obligation of the Company enforceable against the Company in accordance
        with its terms except (i) as limited by applicable bankruptcy, insolvency,
        reorganization, moratorium and other laws of general application affecting
        enforcement of creditors’ rights generally and (ii) as limited by laws relating
        to the availability of specific performance, injunctive relief or other
        equitable remedies.

       

      (c)         
        No
        Conflicts. 
        The execution, delivery and performance of the Transaction Documents by the
        Company and the consummation by the Company of the other transactions
        contemplated thereby do not and will not: (i) conflict with or violate any
        provision of the Company’s or any Subsidiary’s certificate or articles of
        incorporation, bylaws or other organizational or charter documents, or (ii)
        conflict with, or constitute a default (or an event that with notice or lapse
        of
        time or both would become a default) under, result in the creation of any
        Lien
        upon any of the properties or assets of the Company or any Subsidiary, or
        give
        to others any rights of termination, amendment, acceleration or cancellation
        (with or without notice, lapse of time or both) of, any agreement, credit
        facility, debt or other instrument (evidencing a Company or Subsidiary debt
        or
        otherwise) or other understanding to which the Company or any Subsidiary
        is a
        party or by which any property or asset of the Company or any Subsidiary
        is
        bound or affected, or (iii) subject to the Required Approvals, conflict with
        or
        result in a violation of any law, rule, regulation, order, judgment, injunction,
        decree or other restriction of any court or governmental authority to which
        the
        Company or a Subsidiary is subject (including federal and state securities
        laws
        and regulations), or by which any property or asset of the Company or a
        Subsidiary is bound or affected; except in the case of each of clauses (ii)
        and
        (iii), such as could not have or reasonably be expected to result in a Material
        Adverse Effect.

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

       

      (d)          
        Filings,
        Consents and Approvals. 
        The Company is not required to obtain any consent, waiver, authorization
        or
        order of, give any notice to, or make any filing or registration with, any
        court
        or other federal, state, local or other governmental authority or other Person
        in connection with the execution, delivery and performance by the Company
        of the
        Transaction Documents, other than , (i) the filing with the Commission of
        the
        Registration Statement, (ii) the notice and/or application(s) to each applicable
        Trading Market for the issuance and sale of the Preferred Stock and Warrants
        and
        the listing of the Underlying Shares for trading thereon in the time and
        manner
        required thereby, (collectively, the “Required
        Approvals”).

       

      (e)        
        Issuance
        of the Securities. 
        The Preferred Stock and the Underlying Shares are duly authorized and, when
        issued and paid for in accordance with the applicable Transaction Documents,
        will be duly and validly issued, fully paid and nonassessable, free and clear
        of
        all Liens imposed by the Company other than restrictions on transfer provided
        for in the Transaction Documents.  The Company has reserved from its duly
        authorized capital stock a number of shares of Common Stock for issuance
        of the
        Underlying Shares at least equal to the Actual Minimum on the date hereof. 

       

      (f)         
        Capitalization. 
        As of the date hereof, the authorized capital stock of the Company consists
        of
        1,000,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock,
        $0.001 par value per share (“Preferred
        Stock”),
        of
        which 33,492,001 shares of Common Stock and no shares of Preferred Stock
        are
        issued and outstanding in the 10QSB as of September 30, 2006.  All of such
        outstanding shares have been validly issued and are fully paid and
        nonassessable.  No shares of Common Stock are subject to preemptive rights
        or any other similar rights or any liens or encumbrances suffered or permitted
        by the Company. 

       

      (g)         
        SEC
        Reports; Financial Statements. 
        The Company has filed all reports required to be filed by it under the
        Securities Act and the Exchange Act, including pursuant to Section 13(a)
        or
        15(d) thereof (the foregoing materials, including the exhibits thereto, being
        collectively referred to herein as the “SEC
        Reports”)
        on a
        timely basis or has received a valid extension of such time of filing and
        has
        filed any such SEC Reports prior to the expiration of any such extension. 
As of their respective dates, the SEC Reports complied in all material respects
        with the requirements of the Securities Act and the Exchange Act and the
        rules
        and regulations of the Commission promulgated thereunder, and none of the
        SEC
        Reports, when filed, contained any untrue statement of a material fact or
        omitted to state a material fact required to be stated therein or necessary
        in
        order to make the statements therein, in light of the circumstances under
        which
        they were made, not misleading.  The financial statements of the Company
        included in the SEC Reports comply in all material respects with applicable
        accounting requirements and the rules and regulations of the Commission with
        respect thereto as in effect at the time of filing.  Such financial
        statements have been prepared in accordance with United States generally
        accepted accounting principles applied on a consistent basis during the periods
        involved (“GAAP”),
        and
        fairly present in all material respects the financial position of the Company
        and its consolidated subsidiaries as of and for the dates thereof and the
        results of operations and cash flows for the periods then ended, subject,
        in the
        case of unaudited statements, to normal, immaterial, year-end audit
        adjustments.

       

      (h)         Material
        Changes. 
        Since the date of the latest audited financial statements included within
        the
        SEC Reports, except as specifically disclosed in the SEC Reports, (i) there
        has
        been no event, occurrence or development that has had or that could reasonably
        be expected to result in a Material Adverse Effect, (ii) the Company has
        not
        altered its method of accounting, (iii)
        the
        Company has not declared or made any dividend or distribution of cash or
        other
        property to its stockholders or purchased, redeemed any shares of its capital
        stock.

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      (i)         
        Litigation. 
        There is no action, suit, inquiry, notice of violation, proceeding or
        investigation pending or, to the knowledge of the Company, threatened against
        or
        affecting the Company, any Subsidiary or any of their respective properties
        before or by any court, arbitrator, governmental or administrative agency
        or
        regulatory authority (federal, state, county, local or foreign) (collectively,
        an “Action”)
        which
        (i) adversely affects or challenges the legality, validity or enforceability
        of
        any of the Transaction Documents or the Securities or (ii) could, if there
        were
        an unfavorable decision, have or reasonably be expected to result in a Material
        Adverse Effect.  Neither the Company nor any Subsidiary, nor any director
        or officer thereof, is or has been the subject of any Action involving a
        claim
        of violation of or liability under federal or state securities laws or a
        claim
        of breach of fiduciary duty.  There has not been, and to the knowledge of
        the Company, there is not pending or contemplated, any investigation by the
        Commission involving the Company or any current or former director or officer
        of
        the Company.  The Commission has not issued any stop order or other order
        suspending the effectiveness of any registration statement filed by the Company
        or any Subsidiary under the Exchange Act or the Securities Act.

       

      (j)         
        Labor
        Relations. 
        No material labor dispute exists or, to the knowledge of the Company, is
        imminent with respect to any of the employees of the Company which could
        reasonably be expected to result in a Material Adverse Effect.

       

      (k)        
        Compliance. 
        Except as set forth in the SEC Reports or on Schedule 3.1(l), neither the
        Company nor any Subsidiary (i) is in material default under or in violation
        of
        (and no event has occurred that has not been waived that, with notice or
        lapse
        of time or both, would result in a default by the Company or any Subsidiary
        under), nor has the Company or any Subsidiary received notice of a claim
        that it
        is in default under or that it is in violation of, any indenture, loan or
        credit
        agreement or any other material agreement or instrument to which it is a
        party
        or by which it or any of its properties is bound (whether or not such default
        or
        violation has been waived).

       

      (l)         
        Regulatory
        Permits. 
        The Company and the Subsidiaries possess all certificates, authorizations
        and
        permits issued by the appropriate federal, state, local or foreign regulatory
        authorities necessary to conduct their respective businesses as described
        in the
        SEC Reports, except where the failure to possess such permits could not have
        or
        reasonably be expected to result in a Material Adverse Effect (“Material
        Permits”),
        and
        neither the Company nor any Subsidiary has received any notice of proceedings
        relating to the revocation or modification of any Material Permit.

       

      (m)         Patents
        and Trademarks. 
        The Company and the Subsidiaries have, or have rights through licenses to
        use,
        all patents, patent applications, trademarks, trademark applications, service
        marks, trade names, copyrights, licenses and other similar rights that are
        necessary or material for use in connection with their respective businesses
        as
        described in the SEC Reports and which the failure to so have could have
        a
        Material Adverse Effect (collectively, the “Intellectual
        Property Rights”). 

       

      (n)         
        Certain
        Fees. 
        No brokerage or finder’s fees or commissions are or will be payable by the
        Company to any broker, financial advisor or consultant, finder, placement
        agent,
        investment banker, bank or other Person with respect to the transactions
        contemplated by this Agreement.  The Purchasers shall have no obligation
        with respect to any fees or with respect to any claims made by or on behalf
        of
        other Persons for fees of a type contemplated in this Section that may be
        due in
        connection with the transactions contemplated by this Agreement.

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

       

      (o)       
         Investment
        Company.
        The
        Company is not, and is not an Affiliate of, and immediately after receipt
        of
        payment for the shares of Preferred Stock, will not be or be an Affiliate
        of, an
“investment company” within the meaning of the Investment Company Act of 1940,
        as amended.  The Company shall conduct its business in a manner so that it
        will not become subject to the Investment Company Act.

       

      (p)      
          Listing
        and Maintenance Requirements. 
        The Company’s Common Stock is registered pursuant to Section 15(d) of the
        Exchange Act, and the Company has taken no action designed to, or which to
        its
        knowledge is likely to have the effect of, terminating the registration of
        the
        Common Stock under the Exchange Act nor has the Company received any
        notification that the Commission is contemplating terminating such
        registration. 

       

      (q)        
        No
        General Solicitation. 
        Neither the Company nor any person acting on behalf of the Company has offered
        or sold any of the Securities by any form of general solicitation or general
        advertising.  The Company has offered the Securities for sale only to the
        Purchasers and certain other “accredited investors” within the meaning of Rule
        501 under the Securities Act.

       

      (r)         
        Acknowledgment
        Regarding Purchasers’ Purchase of Securities. 
        The Company acknowledges and agrees that each of the Purchasers is acting
        solely
        in the capacity of an arm’s length purchaser with respect to the Transaction
        Documents and the transactions contemplated hereby.  The Company further
        acknowledges that no Purchaser is acting as a financial advisor or fiduciary
        of
        the Company (or in any similar capacity) with respect to this Agreement and
        the
        transactions contemplated hereby and any advice given by any Purchaser or
        any of
        their respective representatives or agents in connection with this Agreement
        and
        the transactions contemplated hereby is merely incidental to the Purchasers’
purchase of the Securities.  The Company further represents to each
        Purchaser that the Company’s decision to enter into this Agreement has been
        based solely on the independent evaluation of the transactions contemplated
        hereby by the Company and its representatives. 

       

      3.2         Representations
        and Warranties of the Purchasers. 
        Each Purchaser hereby, for itself and for no other Purchaser, represents
        and
        warrants as of the date hereof and as of the Closing Date to the Company
        as
        follows:

       

      (a)          Organization;
        Authority. 
        Such Purchaser is an entity duly organized, validly existing and in good
        standing under the laws of the jurisdiction of its organization with full
        right,
        corporate or partnership power and authority to enter into and to consummate
        the
        transactions contemplated by the Transaction Documents and otherwise to carry
        out its obligations thereunder. The execution, delivery and performance by
        such
        Purchaser of the transactions contemplated by this Agreement have been duly
        authorized by all necessary corporate or similar action on the part of such
        Purchaser.  Each Transaction Document to which it is a party has been duly
        executed by such Purchaser, and when delivered by such Purchaser in accordance
        with the terms hereof, will constitute the valid and legally binding obligation
        of such Purchaser, enforceable against it in accordance with its terms, except
        (i) as limited by general equitable principles and applicable bankruptcy,
        insolvency, reorganization, moratorium and other laws of general application
        affecting enforcement of creditors’ rights generally, (ii) as limited by laws
        relating to the availability of specific performance, injunctive relief or
        other
        equitable remedies and (iii) insofar as indemnification and contribution
        provisions may be limited by applicable law.

       

      (b)         Purchaser
        Representation. 
        Such Purchaser understands that the Securities are “restricted securities” and
        have not been registered under the Securities Act or any applicable state
        securities law and is acquiring the Securities as principal for its own account
        and not with a view to or for distributing or reselling such Securities or
        any
        part thereof, has no present intention of distributing any of such Securities
        and has no arrangement or understanding with any other persons regarding
        the
        distribution of such Securities (this representation and warranty not limiting
        such Purchaser’s right to sell the Securities pursuant to the Registration
        Statement or otherwise in compliance with applicable federal and state
        securities laws).  Such Purchaser is acquiring the Securities hereunder in
        the ordinary course of its business. Such Purchaser does not have any agreement
        or understanding, directly or indirectly, with any Person to distribute any
        of
        the Securities.

       

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

       

      (c)         Purchaser
        Status. 
        At the time such Purchaser was offered the Securities, it was, and at the
        date
        hereof it is, and on each date on which it exercises any Warrants, it will
        be
        either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2),
        (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified
        institutional buyer” as defined in Rule 144A(a) under the Securities Act. 
Such Purchaser is not required to be registered as a broker-dealer under
        Section
        15 of the Exchange Act.

       

      (d)        
        Experience
        of Such Purchaser. 
        Such Purchaser, either alone or together with its representatives, has such
        knowledge, sophistication and experience in business and financial matters
        so as
        to be capable of evaluating the merits and risks of the prospective investment
        in the Securities, and has so evaluated the merits and risks of such
        investment. Such Purchaser is able to bear the economic risk of an
        investment in the Securities and, at the present time, is able to afford
        a
        complete loss of such investment.

       

      (e)        
        General
        Solicitation. 
        Such Purchaser is not purchasing the Securities as a result of any
        advertisement, article, notice or other communication regarding the Securities
        published in any newspaper, magazine or similar media or broadcast over
        television or radio or presented at any seminar or any other general
        solicitation or general advertisement.

       

      (f)        
         Certain
        Trading Activities.
         Such Purchaser has not, directly or indirectly, nor has any Person acting
        on behalf of or pursuant to any understanding with such Purchaser, engaged
        in
        (i) any Short Sales (defined below) involving the Company’s securities preceding
        the date hereof or (ii) any transactions in any securities of the Company
        following the date on which such Purchaser was aware of this Transaction
        (other
        than this Transaction); provided, however, that the restrictions contained
        in
        this Section 3.2(f) shall not apply after the date that the Company publicly
        discloses the consummation of the transactions contemplated hereby.  For
        purposes of this Section, “Short Sales” include, without limitation, all types
        of direct and indirect stock pledges, forward sale contracts, options, puts,
        calls, short sales, swaps and similar arrangements (including on a total
        return
        basis), and sales and other transactions through non-US broker dealers or
        foreign regulated brokers having the effect of hedging the securities or
        investment made under this Agreement.

       

      (g)         Material
        Non-Public Information. 
        Such Purchaser understands that any material non-public information provided
        to
        such Purchaser pursuant to a confidentiality agreement is preliminary and
        subject to change at any time prior to any public announcement, if any. 
Such Purchaser acknowledges that there can be no assurance that the Company
        will
        consummate or execute any transaction or agreement disclosed to such Purchaser
        and considered by the Company to be material non-public information.  Such
        Purchaser hereby represents that it is not entering into this Agreement solely
        on the basis of any material non-public information provided to such
        Purchaser.

       

      (h)         Regulation
        S.     
        The Purchaser is not acquiring the Securities for the account or benefit
        of,
        directly or indirectly, any U.S. Person.  The Purchaser is not a U.S.
        Person. The Purchaser is acquiring the Securities for investment only and
        not
        with a view to resale or distribution and, in particular, it has no intention
        to
        distribute either directly or indirectly any of the Securities in the United
        States or to U.S. Persons.  The Purchaser acknowledges that the Purchaser
        has not acquired the Securities as a result of, and will not itself engage
        in,
        any “directed selling efforts” (as defined in Regulation S under the 1933 Act)
        in the United States in respect of the Securities which would include any
        activities undertaken for the purpose of, or that could reasonably be expected
        to have the effect of, conditioning the market in the United States for the
        resale of the Securities; provided, however, that the Purchaser may sell
        or
        otherwise dispose of the Securities pursuant to registration of the Securities
        pursuant to the 1933 Act and any applicable state and provincial securities
        laws
        or under an exemption from such registration requirements and as otherwise
        provided herein.

       

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

      

       

      The
        Company acknowledges and agrees that each Purchaser does not make or has
        not
        made any representations or warranties with respect to the transactions
        contemplated hereby other than those specifically set forth in this Section
        3.2.

       

       

      ARTICLE
        IV

      OTHER
        AGREEMENTS OF THE PARTIES

       

      4.1          Transfer
        Restrictions.

       

      (a)        
        The Securities may only be disposed of in compliance with state and federal
        securities laws.  In connection with any transfer of Securities other than
        pursuant to an effective registration statement or Rule 144, to the Company
        or
        to an affiliate of a Purchaser or in connection with a pledge as contemplated
        in
        Section 4.1(b), the Company may require the transferor thereof to provide
        to the
        Company an opinion of counsel selected by the transferor and reasonably
        acceptable to the Company, the form and substance of which opinion shall
        be
        reasonably satisfactory to the Company, to the effect that such transfer
        does
        not require registration of such transferred Securities under the Securities
        Act.  As a condition of transfer, any such transferee shall agree in
        writing to be bound by the terms of this Agreement and shall have the rights
        of
        a Purchaser under this Agreement and the Registration Rights
        Agreement.

       

      (b)        
        The Purchasers agree to the imprinting, so long as is required by this Section
        4.1(b), of a legend on any of the Securities substantially in the following
        form:

       

      [NEITHER]
        THESE SECURITIES [NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
        [EXERCISABLE] [CONVERTIBLE]] HAVE [NOT] BEEN REGISTERED WITH THE SECURITIES
        AND
        EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
        UPON
        AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
        (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
        TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
        TO
        AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
        REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
        APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
        TO
        THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
        ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON
        EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
        MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

       

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

      

       

      The
        Company acknowledges and agrees that a Purchaser may from time to time pledge
        pursuant to a bona fide margin agreement with a registered broker-dealer
        or
        grant a security interest in some or all of the Securities to a financial
        institution that is an “accredited investor” as defined in Rule 501(a) under the
        Securities Act and who agrees to be bound by the provisions of this Agreement
        and the Registration Rights Agreement and, if required under the terms of
        such
        arrangement, such Purchaser may transfer pledged or secured Securities to
        the
        pledgees or secured parties.  Such a pledge or transfer would not be
        subject to approval of the Company and no legal opinion of legal counsel
        of the
        pledgee, secured party or pledgor shall be required in connection
        therewith.  Further, no notice shall be required of such pledge.  At
        the appropriate Purchaser’s expense, the Company will execute and deliver such
        reasonable documentation as a pledgee or secured party of Securities may
        reasonably request in connection with a pledge or transfer of the Securities,
        including, if the Securities are subject to registration pursuant to the
        Registration Rights Agreement, the preparation and filing of any required
        prospectus supplement under Rule 424(b)(3) under the Securities Act or other
        applicable provision of the Securities Act to appropriately amend the list
        of
        Selling Stockholders thereunder.

       

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

       

      (c)         
        Certificates evidencing the Underlying Shares shall not contain any legend
        (including the legend set forth in Section 4.1(b) hereof): (i) while a
        registration statement (including the Registration Statement) covering the
        resale of such security is effective under the Securities Act, or (ii) following
        any sale of such Underlying Shares pursuant to Rule 144, or (iii) if such
        Underlying Shares are eligible for sale under Rule 144(k), or (iv) if such
        legend is not required under applicable requirements of the Securities Act
        (including judicial interpretations and pronouncements issued by the staff
        of
        the Commission). The Company shall cause its counsel to issue a legal opinion
        to
        the Company’s transfer agent promptly after the Effective Date if required by
        the Company’s transfer agent to effect the removal of the legend hereunder. If
        all or any shares of Preferred Stock or any portion of a Warrant is converted
        or
        exercised (as applicable) at a time when there is an effective registration
        statement to cover the resale of the Underlying Shares, or if such Underlying
        Shares may be sold under Rule 144(k) or if such legend is not otherwise required
        under applicable requirements of the Securities Act (including judicial
        interpretations thereof) then such Underlying Shares shall be issued free
        of all
        legends.  The Company agrees that following the Effective Date or at such
        time as such legend is no longer required under this Section 4.1(c), it will,
        no
        later than seven Trading Days following the delivery by a Purchaser to the
        Company or the Company’s transfer agent of a certificate representing Underlying
        Shares, as applicable, issued with a restrictive legend (such fifth Trading
        Day,
        the “Legend
        Removal Date”),
        deliver or cause to be delivered to such Purchaser a certificate representing
        such shares that is free from all restrictive and other legends.  The
        Company may not make any notation on its records or give instructions to
        any
        transfer agent of the Company that enlarge the restrictions on transfer set
        forth in this Section.

       

      (d)        
        Each Purchaser, severally and not jointly with the other Purchasers, agrees
        that
        the removal of the restrictive legend from certificates representing Securities
        as set forth in this Section 4.1 is predicated upon the Company’s reliance that
        the Purchaser will sell any Securities pursuant to either the registration
        requirements of the Securities Act, including any applicable prospectus delivery
        requirements, or an exemption therefrom.

       

      4.2         Acknowledgment
        of Dilution. 
        The Company acknowledges that the issuance of the Securities may result in
        dilution of the outstanding shares of Common Stock, which dilution may be
        substantial under certain market conditions.  The Company further
        acknowledges that its obligations under the Transaction Documents, including
        without limitation its obligation to issue the Underlying Shares pursuant
        to the
        Transaction Documents, are unconditional and absolute and not subject to
        any
        right of set off, counterclaim, delay or reduction, regardless of the effect
        of
        any such dilution or any claim the Company may have against any Purchaser
        and
        regardless of the dilutive effect that such issuance may have on the ownership
        of the other stockholders of the Company.

       

      4.3         Furnishing
        of Information. 
        As long as any Purchaser owns Securities, the Company covenants to timely
        file
        (or obtain extensions in respect thereof and file within the applicable grace
        period) all reports required to be filed by the Company after the date hereof
        pursuant to the Exchange Act.  As long as any Purchaser owns Securities, if
        the Company is not required to file reports pursuant to the Exchange Act,
        it
        will prepare and furnish to the Purchasers and make publicly available in
        accordance with Rule 144(c) such information as is required for the Purchasers
        to sell the Securities under Rule 144.  The Company further covenants that
        it will take such further action as any holder of Securities may reasonably
        request, all to the extent required from time to time to enable such Person
        to
        sell such Securities without registration under the Securities Act within
        the
        limitation of the exemptions provided by Rule 144.

       

      4.4         Conversion
        and Exercise Procedures. 
        The form of Notice of Exercise included in the Warrants and the Notice of
        Conversion included in the Certificate of Designation set forth the totality
        of
        the procedures required of the Purchasers in order to exercise the Warrants
        or
        convert the Preferred Stock.  No additional legal opinion or other
        information or instructions shall be required of the Purchasers to exercise
        their Warrants or convert their Preferred Stock.  The Company shall honor
        exercises of the Warrants and conversions of the Preferred Stock and shall
        deliver Underlying Shares in accordance with the terms, conditions and time
        periods set forth in the Transaction Documents.

       

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

      

       

      4.5         Securities
        Laws Disclosure; Publicity. 
        The Company agrees that within four Trading Days after the Closing Date,
        the
        Company shall issue a Current Report on Form 8-K disclosing the material
        terms
        of the transactions contemplated hereby, and shall attach the Transaction
        Documents thereto.  The Company and each Purchaser shall consult with each
        other in issuing any other press releases with respect to the transactions
        contemplated hereby, and neither the Company nor any Purchaser shall issue
        any
        such press release or otherwise make any such public statement without the
        prior
        consent of the Company, with respect to any press release of any Purchaser,
        or
        without the prior consent of each Purchaser, with respect to any press release
        of the Company, which consent shall not unreasonably be withheld, except
        if such
        disclosure is required by law, in which case the disclosing party shall promptly
        provide the other party with prior notice of such public statement or
        communication.

       

      4.6         Non-Public
        Information. 
        The Company covenants and agrees that neither it nor any other Person acting
        on
        its behalf will provide any Purchaser or its agents or counsel with any
        information that the Company believes constitutes material non-public
        information, unless prior thereto such Purchaser shall have executed a written
        agreement regarding the confidentiality and use of such information.  The
        Company understands and confirms that each Purchaser shall be relying on
        the
        foregoing representations in effecting transactions in securities of the
        Company.

       

      

      4.7        
        Reservation
        and Listing of Securities.  
        The Company shall maintain a reserve from its duly authorized shares of Common
        Stock for issuance pursuant to the Transaction Documents in such amount as
        may
        be required to fulfill its obligations in full under the Transaction
        Documents.

       

      4.8        
        Equal
        Treatment of Purchasers. 
        No consideration shall be offered or paid to any person to amend or consent
        to a
        waiver or modification of any provision of any of the Transaction Documents
        unless the same consideration is also offered to all of the parties to the
        Transaction Documents.  For clarification purposes, this provision
        constitutes a separate right granted to each Purchaser by the Company and
        negotiated separately by each Purchaser, and is intended to treat for the
        Company the Purchasers as a class and shall not in any way be construed as
        the
        Purchasers acting in concert or as a group with respect to the purchase,
        disposition or voting of Securities or otherwise.

       

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

      

       

      ARTICLE
        V

      MISCELLANEOUS

       

      5.1          
        Fees
        and Expenses. 
        Except as expressly set forth in the Transaction Documents to the contrary,
        each
        party shall pay the fees and expenses of its advisers, counsel, accountants
        and
        other experts, if any, and all other expenses incurred by such party incident
        to
        the negotiation, preparation, execution, delivery and performance of this
        Agreement.  The Company shall pay all transfer agent fees, stamp taxes and
        other taxes and duties levied in connection with the issuance of any
        Securities.

       

      5.2         Entire
        Agreement. 
        The Transaction Documents, together with the exhibits and schedules thereto,
        contain the entire understanding of the parties with respect to the subject
        matter hereof and supersede all prior agreements and understandings, oral
        or
        written, with respect to such matters, which the parties acknowledge have
        been
        merged into such documents, exhibits, and schedules.

       

      5.3         Notices. 
        Any and all notices or other communications or deliveries required or permitted
        to be provided hereunder shall be in writing and shall be deemed given and
        effective on the earliest of (a) the date of transmission, if such notice
        or
        communication is delivered via facsimile at the facsimile number set forth
        on
        the signature pages attached hereto prior to 5:30 p.m. (New York City time)
        on a
        Trading Day, (b) the next Trading Day after the date of transmission, if
        such
        notice or communication is delivered via facsimile at the facsimile number
        set
        forth on the signature pages attached hereto on a day that is not a Trading
        Day
        or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the
        second
        Trading Day following the date of mailing, if sent by U.S. nationally recognized
        overnight courier service, or (d) upon actual receipt by the party to whom
        such
        notice is required to be given.  The address for such notices and
        communications shall be as set forth on the signature pages attached
        hereto.

       

      5.4         Amendments;
        Waivers. 
        No provision of this Agreement may be waived or amended except in a written
        instrument signed, in the case of an amendment, by the Company and each
        Purchaser or, in the case of a waiver, by the party against whom enforcement
        of
        any such waiver is sought.  No waiver of any default with respect to any
        provision, condition or requirement of this Agreement shall be deemed to
        be a
        continuing waiver in the future or a waiver of any subsequent default or
        a
        waiver of any other provision, condition or requirement hereof, nor shall
        any
        delay or omission of either party to exercise any right hereunder in any
        manner
        impair the exercise of any such right.

       

      5.5         Construction. 
        The headings herein are for convenience only, do not constitute a part of
        this
        Agreement and shall not be deemed to limit or affect any of the provisions
        hereof.  The language used in this Agreement will be deemed to be the
        language chosen by the parties to express their mutual intent, and no rules
        of
        strict construction will be applied against any party.

       

      5.6         Successors
        and Assigns. 
        This Agreement shall be binding upon and inure to the benefit of the parties
        and
        their successors and permitted assigns.  The Company may not assign this
        Agreement or any rights or obligations hereunder without the prior written
        consent of Purchaser.  Any Purchaser may assign any or all of its rights
        under this Agreement and the Registration Rights Agreement to any Person
        to whom
        such Purchaser assigns or transfers any Securities, provided such transferee
        agrees in writing to be bound, with respect to the transferred Securities,
        by
        the provisions hereof that apply to the “Purchasers”.

       

      5.7         No
        Third-Party Beneficiaries. 
        This Agreement is intended for the benefit of the parties hereto and their
        respective successors and permitted assigns and is not for the benefit of,
        nor
        may any provision hereof be enforced by, any other Person.

       

      5.8         Governing
        Law. 
        All questions concerning the construction, validity, enforcement and
        interpretation of the Transaction Documents shall be governed by and construed
        and enforced in accordance with the internal laws of the State of Illinois,
        without regard to the principles of conflicts of law thereof.  Each party
        agrees that all legal proceedings concerning the interpretations, enforcement
        and defense of the transactions contemplated by this Agreement and any other
        Transaction Documents (whether brought against a party hereto or its respective
        affiliates, directors, officers, shareholders, employees or agents) shall
        be
        commenced exclusively in the state and federal courts sitting in DuPage County,
        Illinois.  Each party hereby irrevocably submits to the exclusive
        jurisdiction of the state and federal courts sitting in DuPage County for
        the
        adjudication of any dispute hereunder or in connection herewith or with any
        transaction contemplated hereby or discussed herein (including with respect
        to
        the enforcement of any of the Transaction Documents), and hereby irrevocably
        waives, and agrees not to assert in any suit, action or proceeding, any claim
        that it is not personally subject to the jurisdiction of any such court,
        that
        such suit, action or proceeding is improper or inconvenient venue for such
        proceeding.  Each party hereby irrevocably waives personal service of
        process and consents to process being served in any such suit, action or
        proceeding by mailing a copy thereof via registered or certified mail or
        overnight delivery (with evidence of delivery) to such party at the address
        in
        effect for notices to it under this Agreement and agrees that such service
        shall
        constitute good and sufficient service of process and notice thereof. 
Nothing contained herein shall be deemed to limit in any way any right to
        serve
        process in any manner permitted by law.  The parties hereby waive all
        rights to a trial by jury.  If either party shall commence an action or
        proceeding to enforce any provisions of the Transaction Documents, then the
        prevailing party in such action or proceeding shall be reimbursed by the
        other
        party for its attorneys’ fees and other costs and expenses incurred with the
        investigation, preparation and prosecution of such action or
        proceeding.

       

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

      

       

      5.9        
        Survival. 
        The representations and warranties contained herein shall survive the Closing
        for a period of 12 months.

       

      5.10       Execution. 
        This Agreement may be executed in two or more counterparts, all of which
        when
        taken together shall be considered one and the same agreement and shall become
        effective when counterparts have been signed by each party and delivered
        to the
        other party, it being understood that both parties need not sign the same
        counterpart.  In the event that any signature is delivered by facsimile
        transmission, such signature shall create a valid and binding obligation
        of the
        party executing (or on whose behalf such signature is executed) with the
        same
        force and effect as if such facsimile signature page were an original
        thereof.

       

      5.11        Severability. 
        If any provision of this Agreement is held to be invalid or unenforceable
        in any
        respect, the validity and enforceability of the remaining terms and provisions
        of this Agreement shall not in any way be affected or impaired thereby and
        the
        parties will attempt to agree upon a valid and enforceable provision that
        is a
        reasonable substitute therefor, and upon so agreeing, shall incorporate such
        substitute provision in this Agreement.

       

      5.12      
        Replacement
        of Securities. 
        If any certificate or instrument evidencing any Securities is mutilated,
        lost,
        stolen or destroyed, the Company shall issue or cause to be issued in exchange
        and substitution for and upon cancellation thereof, or in lieu of and
        substitution therefor, a new certificate or instrument, but only upon receipt
        of
        evidence reasonably satisfactory to the Company of such loss, theft or
        destruction and customary and reasonable indemnity, if requested.  The
        applicants for a new certificate or instrument under such circumstances shall
        also pay any reasonable third-party costs associated with the issuance of
        such
        replacement Securities.

       

      5.13       Remedies. 
        In addition to being entitled to exercise all rights provided herein or granted
        by law, including recovery of damages, each of the Purchasers and the Company
        will be entitled to specific performance under the Transaction Documents. 
The parties agree that monetary damages may not be adequate compensation
        for any
        loss incurred by reason of any breach of obligations described in the foregoing
        sentence and hereby agrees to waive in any action for specific performance
        of
        any such obligation the defense that a remedy at law would be
        adequate.

       

      5.14       Independent
        Nature of Purchasers’ Obligations and Rights. 
        The obligations of each Purchaser under any Transaction Document are several
        and
        not joint with the obligations of any other Purchaser, and no Purchaser shall
        be
        responsible in any way for the performance of the obligations of any other
        Purchaser under any Transaction Document.  Nothing contained herein or in
        any Transaction Document, and no action taken by any Purchaser pursuant thereto,
        shall be deemed to constitute the Purchasers as a partnership, an association,
        a
        joint venture or any other kind of entity, or create a presumption that the
        Purchasers are in any way acting in concert or as a group with respect to
        such
        obligations or the transactions contemplated by the Transaction Document. 
Each Purchaser shall be entitled to independently protect and enforce its
        rights, including without limitation, the rights arising out of this Agreement
        or out of the other Transaction Documents, and it shall not be necessary
        for any
        other Purchaser to be joined as an additional party in any proceeding for
        such
        purpose.  Each Purchaser has been represented by its own separate legal
        counsel in their review and negotiation of the Transaction Documents.  The
        Company has elected to provide all Purchasers with the same terms and
        Transaction Documents for the convenience of the Company and not because
        it was
        required or requested to do so by the Purchasers.

       

      
        [SIGNATURE
          PAGE FOLLOWS]

      

       

      
        
          
          

        

        
          17

          
            

          

        

        
          
          

        

      

      

      IN
        WITNESS WHEREOF, the parties hereto have caused this Securities Purchase
        Agreement to be duly executed by their respective authorized signatories
        as of
        the date first indicated above.

       

       

      
        	
                BIO-BRIDGE
                  SCIENCE, INC.

              	 	
                Address
                  for Notice:

              
	
                 

              	 	
                 

              
	
                By:

              	
                 

              	 	
                BIO-BRIDGE
                  SCIENCE, INC.

              
	
                 

              	
                Name:
                  Liang Qiao, MD

              	 	
                1211
                  West 22nd
                  Street, Suite 615

              
	
                 

              	
                Title:
                  Chairman & Chief Executive Officer

              	 	
                Oak
                  Brook, IL 60523, USA

              
	 	 	 	 

      

       

       

      With
        a
        copy to (which shall not constitute notice):

      Lisa
        Klein, Esq.

      Richardson
        & Patel LLP

      10900
        Wilshire Blvd., Suite 500 

      Los
        Angeles, CA. 90024 

      Telephone:
        310.208.1182 

      Fax:
        310.208.1154 

       

      

      [REMAINDER
        OF PAGE INTENTIONALLY LEFT BLANK

      SIGNATURE
        PAGE FOR PURCHASER FOLLOWS]

      

        
          
            
            

          

          
            18

            
              

            

          

          
            
            

          

        

Exhibit
        List
        of Purchasers

       

      
        	
                Name

              	
                Subscription
                  Amount (USD$)

              	
                ID
                  Number

              	
                Address

              
	
                Climax
                  Holdings Pty. Limited

              	
                750,000

              	
                ABN
                  57054294316

              	
                6/3
                  Central Avenue, Thornleign NSW 2120, Australia

              
	
                NFR
                  Investments Pty. Ltd.

              	
                750,000

              	
                ABN
                  11003938850

              	
                6/3
                  Central Avenue, Thornleign NSW 2120, Australia

              
	
                Cheung
                  Hin Shun Anthony

              	
                1,500,000

              	 	
                Hong
                  Kong SAR

              

      

       

      
        
          
          

        

        
          19

          
            

          

        

        
          
          

        

      

       

      PURCHASER
        SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT

       

      IN
        WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement
        to be duly executed by their respective authorized signatories as of the
        date
        first indicated above.

       

      
        
          	
                  Name
                    of Investing Entity:

                	 
	
                  Signature
                    of Authorized Signatory of Investing Entity:

                	 
	
                  Name
                    of Authorized Signatory:

                	 
	
                  Title
                    of Authorized Signatory:

                	 
	
                  Email
                    Address of Authorized Signatory:

                	 
	
                  Tax
                    ID number of Investing Entity:

                	 

        

      

       

      Address
        for Notice of Investing Entity:

       

      Address
        for Delivery of Securities for Investing Entity (if not same as
        above):

       

      Subscription
        Amount:

      Shares
        of
        Preferred Stock:

      Warrant
        Shares:

      
 

      [SIGNATURE
        PAGES CONTINUE] 

       

       

      
        
          
          

        

        
          20Exhibit
      10.13

     

    NEITHER
      THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE
      BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
      COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
      MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
      STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
      OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
      SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
      EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
      SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

     

    January________,
      2007       W- 2007-01   

     

    COMMON
      STOCK PURCHASE WARRANT

     

    To
      Purchase 750,000 Shares of Common Stock of

     

    BIO-BRIDGE
      SCIENCE, INC.

     

    THIS
      COMMON STOCK PURCHASE WARRANT (the “Warrant”)
      certifies that, for value received, _______________ (the “Holder”),
      is
      entitled, upon the terms and subject to the limitations on exercise and the
      conditions hereinafter set forth, at any time on or after the date hereof (the
      “Initial
      Exercise Date”)
      and on
      or prior to the close of business on the third anniversary of the Initial
      Exercise Date (the “Termination
      Date”)
      but
      not thereafter, to subscribe for and purchase from BIO-BRIDGE SCIENCE, Inc.,
      a
      Delaware corporation (the “Company”)
      750,000 shares
      (the “Warrant
      Shares”)
      of
      Common Stock, par value $0.001 per share, of the Company (the “Common
      Stock”). 
      The purchase price of one share of Common Stock under this Warrant shall be
      equal to the Exercise Price, as defined in Section 2(b).

     

    Section
      1.              
      Definitions. 
      Capitalized terms used and not otherwise defined herein shall have the meanings
      set forth in that certain Securities Purchase Agreement (the “Purchase
      Agreement”),
      dated
      January _______, 2007, among the Company and the purchasers signatory
      thereto.

     

    Section
      2.              
      Exercise.

     

    a)        Exercise
      of Warrant. 
      Exercise of the purchase rights represented by this Warrant may be made at
      any
      time or times on or after the Initial Exercise Date and on or before the
      Termination Date by delivery to the Company of a duly executed facsimile copy
      of
      the Notice of Exercise Form annexed hereto (or such other office or agency
      of
      the Company as it may designate by notice in writing to the registered Holder
      at
      the address of such Holder appearing on the books of the Company); provided,
      however,
      within
      5 Trading Days of the date said Notice of Exercise is delivered to the Company,
      the Holder shall have surrendered this Warrant to the Company and the Company
      shall have received payment of the aggregate Exercise Price of the shares
      thereby purchased by wire transfer or cashier’s check drawn on a United States
      bank.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    b)         
       Exercise
      Price. 
      The exercise price of the Common Stock under this Warrant shall be $1.00, (the
      “Exercise
      Price”).

     

    

     

    c)            
      Mechanics
      of Exercise.

     

    i.    Authorization
      of Warrant Shares. 
      The Company covenants that all Warrant Shares which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise
      of the purchase rights represented by this Warrant, be duly authorized, validly
      issued, fully paid and nonassessable and free from all taxes, liens and charges
      in respect of the issue thereof (other than taxes in respect of any transfer
      occurring contemporaneously with such issue).  The Company covenants that
      during the period the Warrant is outstanding, it will reserve from its
      authorized and unissued Common Stock a sufficient number of shares to provide
      for the issuance of the Warrant Shares upon the exercise of any purchase rights
      under this Warrant.  The Company further covenants that its issuance of
      this Warrant shall constitute full authority to its officers who are charged
      with the duty of executing stock certificates to execute and issue the necessary
      certificates for the Warrant Shares upon the exercise of the purchase rights
      under this Warrant.  The Company will take all such reasonable action as
      may be necessary to assure that such Warrant Shares may be issued as provided
      herein without violation of any applicable law or regulation, or of any
      requirements of the Trading Market upon which the Common Stock may be
      listed.

     

    ii.    
      Delivery
      of Certificates Upon Exercise. 
      Certificates for shares purchased hereunder shall be transmitted by the transfer
      agent of the Company to the Holder by crediting the account of the Holder’s
      prime broker with the Depository Trust Company through its Deposit Withdrawal
      Agent Commission (“DWAC”)
      system
      if the Company is a participant in such system, and otherwise by physical
      delivery to the address specified by the Holder in the Notice of Exercise within
      10 Trading Days from the delivery to the Company of the Notice of Exercise
      Form,
      surrender of this Warrant and payment of the aggregate Exercise Price as set
      forth above (“Warrant
      Share Delivery Date”). 
      This Warrant shall be deemed to have been exercised on the date the Exercise
      Price is received by the Company.  The Warrant Shares shall be deemed to
      have been issued, and Holder or any other person so designated to be named
      therein shall be deemed to have become a holder of record of such shares for
      all
      purposes, as of the date the Warrant has been exercised by payment to the
      Company of the Exercise Price and all taxes required to be paid by the Holder,
      if any, prior to the issuance of such shares, have been paid.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    iii.   
      Delivery
      of New Warrants Upon Exercise. 
      If this Warrant shall have been exercised in part, the Company shall, at the
      time of delivery of the certificate or certificates representing Warrant Shares,
      deliver to Holder a new Warrant evidencing the rights of Holder to purchase
      the
      unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
      in all other respects be identical with this Warrant.

     

    iv.  No
      Fractional Shares or Scrip. 
      No fractional shares or scrip representing fractional shares shall be issued
      upon the exercise of this Warrant.  

     

    v.    
      Charges,
      Taxes and Expenses. 
      Issuance of certificates for Warrant Shares shall be made without charge to
      the
      Holder for any issue or other incidental expense in respect of the issuance
      of
      such certificate, all of which taxes and expenses shall be paid by the Company,
      and such certificates shall be issued in the name of the Holder or in such
      name
      or names as may be directed by the Holder; provided,
      however,
      that in
      the event certificates for Warrant Shares are to be issued in a name other
      than
      the name of the Holder, this Warrant when surrendered for exercise shall be
      accompanied by the Assignment Form attached hereto duly executed by the Holder;
      and the Company may require, as a condition thereto, the payment of a sum
      sufficient to reimburse it for any transfer tax incidental thereto.

     

    vi.   
      Closing
      of Books. 
      The Company will not close its stockholder books or records in any manner which
      prevents the timely exercise of this Warrant, pursuant to the terms
      hereof.

     

    Section
      3.              
      Certain Adjustment.

     

    a)            
      Stock
      Dividends and Splits.
      If the
      Company, at any time while this Warrant is outstanding: (A) pays a stock
      dividend or otherwise make a distribution or distributions on shares of its
      Common Stock or any other equity or equity equivalent securities payable in
      shares of Common Stock (which, for avoidance of doubt, shall not include any
      shares of Common Stock issued by the Company pursuant to this Warrant), (B)
      subdivides outstanding shares of Common Stock into a larger number of shares,
      (C) combines (including by way of reverse stock split) outstanding shares of
      Common Stock into a smaller number of shares, or (D) issues by reclassification
      of shares of the Common Stock any shares of capital stock of the Company, then
      in each case the Exercise Price shall be multiplied by a fraction of which
      the
      numerator shall be the number of shares of Common Stock (excluding treasury
      shares, if any) outstanding before such event and of which the denominator
      shall
      be the number of shares of Common Stock outstanding after such event and the
      number of shares issuable upon exercise of this Warrant shall be proportionately
      adjusted.  Any adjustment made pursuant to this Section 3(a) shall become
      effective immediately after the record date for the determination of
      stockholders entitled to receive such dividend or distribution and shall become
      effective immediately after the effective date in the case of a subdivision,
      combination or re-classification.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    b)           
      Calculations.
      Calculations under this Section 3 shall be made to the nearest cent or the
      nearest 1/100th of a share, as the case may be. The number of shares of Common
      Stock outstanding at any given time shall not includes shares of Common Stock
      owned or held by or for the account of the Company, and the description of
      any
      such shares of Common Stock shall be considered on issue or sale of Common
      Stock.  For purposes of this Section 3, the number of shares of Common
      Stock deemed to be issued and outstanding as of a given date shall be the sum
      of
      the number of shares of Common Stock (excluding treasury shares, if any) issued
      and outstanding.

     

    c)            
      Notice
      to Holders.

     

    Adjustment
      to Exercise Price.
      Whenever the Exercise Price is adjusted pursuant to this Section 3, the Company
      shall promptly mail to each Holder a notice setting forth the Exercise Price
      after such adjustment and setting forth a brief statement of the facts requiring
      such adjustment.

     

    d)           
      Reorganizations,
      etc. 
In
      case, at any time during the Exercise Period, of any capital reorganization,
      of
      any reclassification of the stock of the Company (other than a change in par
      value or from par value to no par value or from no par value to par value or
      as
      a result of a stock dividend or subdivision, split-up or combination of shares),
      or the consolidation or merger of the Company with or into another corporation
      (other than a consolidation or merger in which the Company is the continuing
      operation and which does not result in any change or reclassification in the
      Warrant Shares) or of the sale of all or substantially all the properties and
      assets of the Company as an entirety to any other corporation, the Company,
      at
      its sole discretion, shall have the right and option to (A) provide 10 days
      prior written notice of such event to the Holder and this Warrant shall
      terminate and be of no further force and effect on and after the effective
      date
      of such capital reorganization or reclassification or the consummation of such
      consolidation, sale or merger; or (B) provide that this Warrant shall, after
      such reorganization, reclassification, consolidation, merger or sale, be
      exercisable for the kind and number of shares of stock or other securities
      or
      property of the Company or of the corporation resulting from such consolidation
      or surviving such merger or to which such properties and assets shall have
      been
      sold to which such holder would have been entitled if he, she or it had held
      the
      Warrant Shares issuable upon the exercise hereof immediately prior to such
      reorganization, reclassification, consolidation, merger or sale.

     

    e)           
      Exempt
      Issuance.
      Notwithstanding the foregoing, no adjustments, nor notices shall be made, paid
      or issued under this Section 3 in respect of an Exempt Issuance.

     

    Section
      4.              
      Transfer
      of Warrant.

     

    a)            
      Transferability. 
      Subject to compliance with any applicable securities laws and the conditions
      set
      forth in Sections 5(a) and 4(d) hereof and to the provisions of Section 4.1
      of
      the Purchase Agreement, this Warrant and all rights hereunder are transferable,
      in whole or in part, upon surrender of this Warrant at the principal office
      of
      the Company, together with a written assignment of this Warrant substantially
      in
      the form attached hereto duly executed by the Holder or its agent or attorney
      and funds sufficient to pay any transfer taxes payable upon the making of such
      transfer.  Upon such surrender and, if required, such payment, the Company
      shall execute and deliver a new Warrant or Warrants in the name of the assignee
      or assignees and in the denomination or denominations specified in such
      instrument of assignment, and shall issue to the assignor a new Warrant
      evidencing the portion of this Warrant not so assigned, and this Warrant shall
      promptly be cancelled.  A Warrant, if properly assigned, may be exercised
      by a new holder for the purchase of Warrant Shares without having a new Warrant
      issued.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    b)           
      New
      Warrants.
      This
      Warrant may be divided or combined with other Warrants upon presentation hereof
      at the aforesaid office of the Company, together with a written notice
      specifying the names and denominations in which new Warrants are to be issued,
      signed by the Holder or its agent or attorney.  Subject to compliance with
      Section 4(a), as to any transfer which may be involved in such division or
      combination, the Company shall execute and deliver a new Warrant or Warrants
      in
      exchange for the Warrant or Warrants to be divided or combined in accordance
      with such notice.

     

    c)            
      Warrant
      Register.
      The
      Company shall register this Warrant, upon records to be maintained by the
      Company for that purpose (the “Warrant
      Register”),
      in
      the name of the record Holder hereof from time to time.  The Company may
      deem and treat the registered Holder of this Warrant as the absolute owner
      hereof for the purpose of any exercise hereof or any distribution to the Holder,
      and for all other purposes, absent actual notice to the contrary.

     

    d)           
      Transfer
      Restrictions.
      If, at
      the time of the surrender of this Warrant in connection with any transfer of
      this Warrant, the transfer of this Warrant shall not be registered pursuant
      to
      an effective registration statement under the Securities Act and under
      applicable state securities or blue sky laws, the Company may require, as a
      condition of allowing such transfer (i) that the Holder or transferee of this
      Warrant, as the case may be, furnish to the Company a written opinion of counsel
      (which opinion shall be in form, substance and scope customary for opinions
      of
      counsel in comparable transactions) to the effect that such transfer may be
      made
      without registration under the Securities Act and under applicable state
      securities or blue sky laws, (ii) that the holder or transferee execute and
      deliver to the Company an investment letter in form and substance acceptable
      to
      the Company and (iii) that the transferee be an “accredited investor” as defined
      in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the
      Securities Act or a qualified institutional buyer as defined in Rule 144A(a)
      under the Securities Act.

     

    Section
      5.              
      Miscellaneous.

     

    a)            
      Title
      to Warrant. 
      Prior to the Termination Date and subject to compliance with applicable laws
      and
      Section 4 of this Warrant, this Warrant and all rights hereunder are
      transferable, in whole or in part, at the office or agency of the Company by
      the
      Holder in person or by duly authorized attorney, upon surrender of this Warrant
      together with the Assignment Form annexed hereto properly endorsed.  The
      transferee shall sign an investment letter in form and substance reasonably
      satisfactory to the Company.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    b)           
      No
      Rights as Shareholder Until Exercise. 
      This Warrant does not entitle the Holder to any voting rights or other rights
      as
      a shareholder of the Company prior to the exercise hereof.  Upon the
      surrender of this Warrant and the payment of the aggregate Exercise Price,
      the
      Warrant Shares so purchased shall be and be deemed to be issued to such Holder
      as the record owner of such shares as of the close of business on the later
      of
      the date of such surrender or payment.

     

    c)            
      Loss,
      Theft, Destruction or Mutilation of Warrant.
      The
      Company covenants that upon receipt by the Company of evidence reasonably
      satisfactory to it of the loss, theft, destruction or mutilation of this Warrant
      or any stock certificate relating to the Warrant Shares, and in case of loss,
      theft or destruction, of indemnity or security reasonably satisfactory to it
      (which, in the case of the Warrant, shall not include the posting of any bond),
      and upon surrender and cancellation of such Warrant or stock certificate, if
      mutilated, the Company will make and deliver a new Warrant or stock certificate
      of like tenor and dated as of such cancellation, in lieu of such Warrant or
      stock certificate.

     

    d)           
      Saturdays,
      Sundays, Holidays, etc. 
      If the last or appointed day for the taking of any action or the expiration
      of
      any right required or granted herein shall be a Saturday, Sunday or a legal
      holiday, then such action may be taken or such right may be exercised on the
      next succeeding day not a Saturday, Sunday or legal holiday.

     

    e)            
      Authorized
      Shares.

     

    The
      Company covenants that during the period the Warrant is outstanding, it will
      reserve from its authorized and unissued Common Stock a sufficient number of
      shares to provide for the issuance of the Warrant Shares upon the exercise
      of
      any purchase rights under this Warrant.  The Company further covenants that
      its issuance of this Warrant shall constitute full authority to its officers
      who
      are charged with the duty of executing stock certificates to execute and issue
      the necessary certificates for the Warrant Shares upon the exercise of the
      purchase rights under this Warrant.  The Company will take all such
      reasonable action as may be necessary to assure that such Warrant Shares may
      be
      issued as provided herein without violation of any applicable law or regulation,
      or of any requirements of the Trading Market upon which the Common Stock may
      be
      listed.

     

    Except
      and to the extent as waived or consented to by the Holder, the Company shall
      not
      by any action, including, without limitation, amending its certificate of
      incorporation or through any reorganization, transfer of assets, consolidation,
      merger, dissolution, issue or sale of securities or any other voluntary action,
      avoid or seek to avoid the observance or performance of any of the terms of
      this
      Warrant, but will at all times in good faith assist in the carrying out of
      all
      such terms and in the taking of all such actions as may be necessary or
      appropriate to protect the rights of Holder as set forth in this Warrant against
      impairment.  Without limiting the generality of the foregoing, the Company
      will (a) not increase the par value of any Warrant Shares above the amount
      payable therefor upon such exercise immediately prior to such increase in par
      value, (b) take all such action as may be necessary or appropriate in order
      that
      the Company may validly and legally issue fully paid and nonassessable Warrant
      Shares upon the exercise of this Warrant, and (c) use commercially reasonable
      efforts to obtain all such authorizations, exemptions or consents from any
      public regulatory body having jurisdiction thereof as may be necessary to enable
      the Company to perform its obligations under this Warrant.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    Before
      taking any action which would result in an adjustment in the number of Warrant
      Shares for which this Warrant is exercisable or in the Exercise Price, the
      Company shall obtain all such authorizations or exemptions thereof, or consents
      thereto, as may be necessary from any public regulatory body or bodies having
      jurisdiction thereof.

     

    f)          
       Jurisdiction.
      All
      questions concerning the construction, validity, enforcement and interpretation
      of this Warrant shall be determined in accordance with the provisions of the
      Purchase Agreement.

     

    g)        
        Restrictions. 
      The Holder acknowledges that the Warrant Shares acquired upon the exercise
      of
      this Warrant, if not registered, will have restrictions upon resale imposed
      by
      state and federal securities laws.

     

    h)       
         Nonwaiver
       
No
      course of dealing or any delay or failure to exercise any right hereunder on
      the
      part of Holder shall operate as a waiver of such right or otherwise prejudice
      Holder’s rights, powers or remedies, notwithstanding the fact that all rights
      hereunder terminate on the Termination Date. 

     

    i)            
      Notices. 
      Any notice, request or other document required or permitted to be given or
      delivered to the Holder by the Company shall be delivered in accordance with
      the
      notice provisions of the Purchase Agreement.

     

    j)          
        Limitation
      of Liability. 
      No provision hereof, in the absence of any affirmative action by Holder to
      exercise this Warrant or purchase Warrant Shares, and no enumeration herein
      of
      the rights or privileges of Holder, shall give rise to any liability of Holder
      for the purchase price of any Common Stock or as a stockholder of the Company,
      whether such liability is asserted by the Company or by creditors of the
      Company.

     

    k)          
      Remedies.
       Holder, in addition to being entitled to exercise all rights granted by
      law, including recovery of damages, will be entitled to specific performance
      of
      its rights under this Warrant.  The Company agrees that monetary damages
      would not be adequate compensation for any loss incurred by reason of a breach
      by it of the provisions of this Warrant and hereby agrees to waive the defense
      in any action for specific performance that a remedy at law would be
      adequate.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    l)             
      Successors
      and Assigns. 
      Subject to applicable securities laws, this Warrant and the rights and
      obligations evidenced hereby shall inure to the benefit of and be binding upon
      the successors of the Company and the successors and permitted assigns of
      Holder.  The provisions of this Warrant are intended to be for the benefit
      of all Holders from time to time of this Warrant and shall be enforceable by
      any
      such Holder or holder of Warrant Shares.

     

    m)           Amendment. 
      This Warrant may be modified or amended or the provisions hereof waived with
      the
      written consent of the Company and the Holder.

     

    n)           
      Severability. 
      Wherever possible, each provision of this Warrant shall be interpreted in such
      manner as to be effective and valid under applicable law, but if any provision
      of this Warrant shall be prohibited by or invalid under applicable law, such
      provision shall be ineffective to the extent of such prohibition or invalidity,
      without invalidating the remainder of such provisions or the remaining
      provisions of this Warrant.

     

    o)           
      Headings. 
      The headings used in this Warrant are for the convenience of reference only
      and
      shall not, for any purpose, be deemed a part of this Warrant.

     

    IN
      WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
      officer thereunto duly authorized.

     

    Dated: 
      January ___, 2007 

     

    
      	
               

            	
              BIO-BRIDGE
                SCIENCE, INC.

            
	
               

            	
               

            
	
               

            	
               

            
	
               

            	
              By:

            	
               

            
	
               

            	
               

            	
              Name:
                Liang Qiao, MD

            
	
               

            	
               

            	
              Title:
                Chairman & Chief Executive
                Officer

            

    

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    NOTICE
      OF EXERCISE

     

    TO:        
      BIO-BRIDGE
      SCIENCE, INC.

     

    (1)  
      The
      undersigned hereby elects to purchase _____________ Warrant Shares of the
      Company pursuant to the terms of the attached Warrant (only if exercised in
      full), and tenders herewith payment of the exercise price in full, together
      with
      all applicable transfer taxes, if any.

     

    (2)  
      Payment
      shall take in the form in lawful money of the United States . The amount is
      ___________.

     

    (3)  
      Please
      issue a certificate or certificates representing said Warrant Shares in the
      name
      of the undersigned or in such other name as is specified below:

     

    The
      Warrant Shares shall be delivered to the following: 

     

    
      
        (4) 
          Accredited
          Investor. 
          The undersigned is an “accredited investor” as defined in Regulation D
          promulgated under the Securities Act of 1933, as amended.

      

    

     

    
      
        (5)
 

    

     

    [SIGNATURE
      OF HOLDER]

     

    
      
        
          	
                  Name
                    of Investing Entity:

                	 
	
                  Signature
                    of Authorized Signatory of Investing Entity:

                	 
	
                  Name
                    of Authorized Signatory:

                	 
	
                  Title
                    of Authorized Signatory:

                	 
	
                  Date:

                	 

        

      

      

        
          
            
            

          

          
            9

            
              

            

          

          
            
            

          

        

      

    

     

    ASSIGNMENT
      FORM

     

    (To
      assign the foregoing warrant, execute

    this
      form
      and supply required information. 

    Do
      not
      use this form to exercise the warrant.)

     

    FOR
      VALUE
      RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
      assigned to

     

                                                                                                               
      whose address is_____________________________

     

    
      	 	
              Dated:

            	
               

            	
              ,

            	
               

            	
               

            
	
               

            
	
               

            	
               

            
	
               

            	
              Holder’s
                Signature:

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
              Holder’s
                Address:

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
               

            	
               

            
	
              Signature
                Guaranteed: 

            	
               

            	
               

            

    

     

     

    NOTE: 
      The signature to this Assignment Form must correspond with the name as it
      appears on the face of the Warrant, without alteration or enlargement or any
      change whatsoever, and must be guaranteed by a bank or trust company. 
Officers of corporations and those acting in a fiduciary or other representative
      capacity should file proper evidence of authority to assign the foregoing
      Warrant.

     

    
      
        
        

      

      
        10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]